News | May 18, 2026
Alembic Pharmaceuticals posts strong Q4 FY26 growth as net profit jumps 29%
US formulations grew 11% to Rs. 564 crore as Alembic enters US branded pharmaceuticals market with launch of Pivya
US formulations grew 11% to Rs. 564 crore as Alembic enters US branded pharmaceuticals market with launch of Pivya
FY26 revenue rises to Rs. 4,359 crore as India’s leading CDMO strengthens global footprint with EU GMP certifications, UK MHRA approval and Europe supplies
Antiviral injection addressing CMV and HSV infections had US market sales of nearly $15 million in the last 12 months
At the institute's 42nd convocation ceremony, Union Minister described its eight-institution MoU initiative as a unique collaborative effort that brings together premier national institutions to create a synergistic research ecosystem
The 38% adjusted EBITDA margin of base business has been supported by robust growth in the CDMO segment
Funding to support clinical development, gene therapy pipeline expansion and GMP manufacturing capabilities
Dr. Reddy’s is the first company to receive Health Canada approval for generic Semaglutide Injection in Canada
Famotidine Injection USP is a generic version of Pepcid injection to be manufactured at its Nagpur facility for the U.S. market
The certification follows an inspection conducted by the Malta Medicines Authority between January 29, 2026, and February 3, 2026
Darolutamide Tablets, 300 mg, had an estimated market size of US$ 3,155 million in the United States
Subscribe To Our Newsletter & Stay Updated
